Please find attached for Ennature Bio Pharma.

IGL/SE/2026-27/53 2nd September, 2026 The Manager (Listing) The Manager (Listing) BSE Limited National Stock Exchange of India Limited 1st Floor, New Trading Ring, Exchange Plaza, C-1, Block G, Rotunda Building, P.J. Towers, Bandra Kurla Complex, Dalal Street, Bandra (East), Mumbai – 400 001 Mumbai- 400 051 Scrip Code: 500201 Symbol: INDIAGLYCO Dear Sirs, Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Investor Presentation for Analyst / Institutional Investor Meeting. Further to our letter bearing no. IGL/SE/2026-27/50 dated 28th August, 2026 and pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith investor presentation for the analyst / institutional investor meeting to be held on 2nd September, 2026. This same is also being hosted on the Company’s website at www.indiaglycols.com. This is for your information and record. Thanking you, Yours truly, For India Glycols Limited Ankur Jain Head (Legal) & Company Secretary Encl: A/a Ennature Biopharma Investor presentation September 2026 Strictly private and confidential Structural Megatrends Accelerating Nutraceutical Demand Worldwide Health & Demographic Trends India Health & Demographic Trends 1.0bn 2.1bn 11% 21% Demographic Shift 60+ population is set to double 2020 2050 2024 2050 74% ~31% ~16% ~11% Lifestyle Disease Lifestyle choices leading to Burden higher chronic conditions Global deaths Insufficiently Obesity2 Diabetes Hypertension Obesity3 attributed to NCDs1 Active Adults Health Supplement Preventive health needs 77% of US adults consume 71% of consumers take Prevalence driving supplement use dietary supplements supplements4 periodically Source: Industry Research, WHO, ICMR, CRN Consumer Survey, LocalCircles Survey. Note: (1) Non-Communicable Diseases. (2) BMI > 30. (3) BMI > 25. (4) Includes herbs vitamins, minerals, fibre and omega. 3 Scaled Botanical Opportunity, Increasingly Driven by Condition-Led Nutrition Botanicals represent a scaled, established segment within the global Consumers are moving from generic products toward supplement opportunity targeted solutions addressing specific health outcomes ~$450bn Women’s Bone, joint and Health muscle health Global Nutraceutical Market Metabolic Gut Health ~$70bn Botanical Ingredients Market Brain Health Operating within a large botanical ingredients market, Ennature Ennature’s science-backed botanical portfolio addresses has built differentiated products around established ingredients high-priority health needs across condition-led categories Source: Industry Research. Ennature's Journey of Value Creation 2008-2013 2014 - 2019 2020 - 2026 Current Legacy Platform Capability Build Portfolio Expansion Science-Led Growth Value Unlock Born from India Glycols’ Built expertise in high Advanced into high- Built a science-led Demerger from India legacy in green chemistry value, plant-based Active quality, standardized portfolio of clinically Glycols and addition of and advanced technology Pharmaceutical botanical extracts validated nutraceutical biopolymer (Guar) Ingredients (APIs) ingredients portfolio has created an integrated natural ingredients platform Building on deep phyto-chemical expertise, Ennature is well positioned to take advantage of the huge opportunity in natural health & wellness space. Three Businesses, One Natural Ingredients Platform Mature core API business generates durable, predictable cash flows, fueling the strategic expansion into high-growth Branded Nutraceutical segment. Nutraceuticals Biopolymers Products: Branded Ingredients, Products: Guar Gum and Speciality Standard Botanical Extracts, CDMO Plant based APIs Gums Relatively New and Growing Products: Thiocolchicoside, segment, High margins Colchicine, Nicotine, Vinpocetine Core business, Growing segment Core business, Stable margins and of Sales moderate growth 16% of Sales 67% Future Growth Engine Fueled by of Sales the Core Portfolio Steady Business with Multiple Growth Prospects Mature, Cash Generative Business Shared expertise across Plant-based APIs, Biopolymers and Nutraceuticals creates a balanced portfolio of resilience, margins and growth • Certificate EU-GMP • Countries • Customers • Export share 1 Established API Franchise Providing a Stable Foundation for Growth Leadership in key APIs led by strong technology platform and quality systems, serving 2 Approved global and domestic pharmaceutical customers 2 Under- evaluation US-DMF Built over the past 15 years, the segment delivers high-value, niche and complex molecules 2 Products while supporting new growth initiatives EU-GMP 1 Scale Nicotine portfolio – Shift towards long-term, higher-value pharmaceutical customers 2 Add 1 new API product a year – Targeting niche, complex molecules Strategies Countries 3 Deepen Regulated market penetration – Broader access to the US, Europe and other regulated markets 150+ Active Customers Export Revenues Product Thiocolchicoside Colchicine Nicotine Vinpocetine Portfolio Muscle Relaxant / Analgesic Anti-inflammatory / Gout Nicotine Replacement Cognitive Health Note: Export mix as of FY26. Diversified Biopolymer (Guar) Platform Positioned for Sustainable 2 Growth Serving all end- markets Broad end-market exposure provides a resilient foundation, while dietary fibre and value- added derivatives drive the next phase of growth 1 Scale Dietary Fibre Applications – Expand participation in food, nutrition and health-focused applications 23+ Countries Key 2 Grow Value-Added Derivatives – Increase the contribution of specialized, application-led solutions Strategies 3 Deepen End-Market Penetration – Grow customer relationships across Active Customers Key End Personal Oil & Gas F&B Paints Textiles Supplements 69% Markets Care Export Revenues Note: Export mix as of FY26. 3 Scaling Branded Nutraceutical Ingredients as the Next Growth Engine USFDA Expanding beyond standardized botanical extracts into higher-value, clinically validated branded ingredients with stronger customer stickiness NSF GMP 1 Strengthen branded portfolio – Deepening expertise across science, clinicals, regulatory and supply chain Flagship Key 2 Build US presence – Local office established for customer coverage and stocking capabilities Branded Strategies ingredients 3 Expand regulated market access – Korea, Europe and Taiwan Branded Ingredients Planned Countries Aspargize Gingeren Maxicuma® Xanthogreen® Berbisol Active Branded Customers Product • Fast-acting Shatavari • Sustained release • High bioavailability at • Fast-acting lutein • Bio-enhanced Portfolio • Targeted for granules low dose esters berberine 83% • Targeted for • Clinical trials Menopause Dysmenorrhea underway Export Revenues Women's Health Women’s Health Bone & Joint Health Eye Health Metabolic Health Note: Export mix as of FY26. Aligned with structural market trends 3 Well Positioned to Capture the Shift Towards High Value Nutraceutical Ingredients Building a differentiated competitive MOAT • Expertise in working with plant based phyto-actives • Investment in science – Clinical studies, patented tech platforms and product patents Nutraceuticals Outlook: • Pharma expertise – Technology, Fully integrated manufacturing from R&D to Establishing branded nutraceuticals semi-formulation and Quality Systems as a differentiated, high-margin growth platform with 2-3 additional • Globally certified quality systems – EU-GMP and US-FDA certified, built for products in the pipeline the world's most regulated markets • Access to India’s centuries old Ayurveda legacy provides an edge in ingredient discovery, validation and formulation Creating Defensibility Through Intellectual Property and Clinical Evidence Innovation and clinical validation transform botanical ingredients into differentiated, globally scalable brands Patented Technology Platforms 9 5 Patents Filed Granted [Showing first 8,000 characters — download PDF for full document]